Novo Nordisk A's Revenue in the fiscal year 2025 $ 309,064.00 millions
Novo Nordisk A's Revenue in the fiscal year 2024 $ 290,403.00 millions
Novo Nordisk A's Revenue in the fiscal year 2023 $ 33,717.55 millions
Novo Nordisk A's Revenue in the fiscal year 2022 $ 25,053.80 millions
Novo Nordisk A's Revenue in the fiscal year 2021 $ 22,398.45 millions
NVO Revenue first quarter 2025 Y/Y Growth Comment
Novo Nordisk A reported Revenue improvement of 37.57% year on year in the first quarter 2025, to $ 15,165.90 millions, this is lower than Novo Nordisk A's recent average Revenue surge of 106.15%.
Looking into first quarter 2025 results within Major Pharmaceutical Preparations industry 100 other companies have achieved higher Revenue growth. While Novo Nordisk A' s Revenue rise of 37.57% ranks overall at the positon no. 1101 in the first quarter 2025.
Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025
Novo Nordisk A's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
301.14 %
19.86 %
-73.83 %
(Dec 31 2024)
NVO's I. Quarter Q/Q Revenue Comment
Novo Nordisk A achieved in the I. Quarter 2025 above company average sequential Revenue jump of 22.55%, to $ 15,165.90 millions, from $12,375.20 millions in the fourth quarter. NVO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 232 other companies have achieved higher Revenue quarter on quarter growth. While Novo Nordisk A's Revenue growth quarter on quarter, overall rank is 4160.
Novo Nordisk A achieved in the I. Quarter 2025 above company average sequential Revenue jump of 22.55%, to $ 15,165.90 millions, from $12,375.20 millions in the fourth quarter. NVO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 232 other companies have achieved higher Revenue quarter on quarter growth. While Novo Nordisk A's Revenue growth quarter on quarter, overall rank is 4160.
Novo Nordisk A's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Dec 31 2025)
12 Months Ending (Dec 31 2024)
12 Months Ending (Dec 31 2023)
12 Months Ending (Dec 31 2022)
12 Months Ending (Dec 31 2021)
Cumulative Revenue 12 Months Ending
$ 309,064.00
$ 290,403.00
$ 33,717.55
$ 25,053.80
$ 22,398.45
Y / Y Revenue Growth (TTM)
6.43 %
761.28 %
34.58 %
11.86 %
15.26 %
Year on Year Revenue Growth Overall
Ranking
# 1101
# 1645
# 0
# 0
#
Seqeuential Revenue Change (TTM)
6.43 %
761.28 %
34.58 %
11.86 %
15.26 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1101
# 1645
# 0
# 0
#
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Novo Nordisk A's cumulative twelve months Revenue were $ 309,064 millions, company would post below average annual Revenue growth of 15.26% year on year, if the fiscal year would end at Dec 31 2025. A slow-down in the Novo Nordisk A's Revenue growth from the 12375.2% growth in Dec 31 2024.
In the Healthcare sector 229 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1101, from total ranking in previous quarter at 1645.
With the quarterly Revenue reported in the Dec 31 2025 period, Novo Nordisk A's cumulative twelve months Revenue were $ 309,064 millions, company would post below average annual Revenue growth of 3.18% year on year, if the fiscal year would end at Dec 31 2025. A slow-down in the Novo Nordisk A's Revenue growth from the 12375.2% growth in Dec 31 2024.
In the Healthcare sector 229 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1101, from total ranking in previous quarter at 1645.
About Novo Nordisk A Revenue Growth Rates (NVO), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
65.67%